Literature DB >> 6159767

Serum beta 2-microglobulin, serum creatinine and bone marrow plasma cells in benign and malignant monoclonal gammopathy.

A Morell, W Riesen.   

Abstract

Serum beta 2-microglobulin concentrations were determined in samples of 65 patients with benign or malignant monoclonal gammopathy. In the group of patients suffering from multiple myeloma or Waldenström's macroglobulinemia the mean beta 2-microglobulin level was significantly higher than in the group with benign monoclonal gammopathy. Values above 3 mg/l were highly indicative of malignant disease and observed in 50% of the myeloma patients. Serum creatinine levels were significantly correlated to beta 2-microglobulin levels. However, mean creatinine concentrations did not significantly differ between the two groups of patients. Plasma cells and lymphoplasmocellular elements containing cytoplasmic immunoglobulin were counted in bone marrow samples of all patients. The counts, expressed in percent of nucleated bone marrow cells, allowed a good discrimination between the benign and the malignant group of patients. Bone marrow from patients with multiple myeloma or macroglobulinemia contained more, from patients with benign monoclonal gammopathy less than 17% plasma cells. No significant correlation was noticed between the extent of this plasmocytic bone marrow infiltration and serum beta 2-microglobulin or creatinine levels.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6159767     DOI: 10.1159/000207216

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  2 in total

1.  Beta 2-microglobulin in haematological malignancies.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1981-03-28

2.  Genetic and clinical studies of serum beta 2-microglobulin levels in haematological malignancies.

Authors:  Y Nakao; H Matsumoto; T Miyazaki; S Watanabe; T Masaoka; K Takatsuki; M Kishihara; N Kobayashi; M Hattori; T Fujita
Journal:  Clin Exp Immunol       Date:  1981-10       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.